

# Beryllium Toxicity In Relation To Chemical Forms and Particle Sizes

<sup>1</sup> Muller C, <sup>2</sup> Salehi F, <sup>2</sup> Mazer B, <sup>3</sup> Truchon G, <sup>4</sup> Chevalier G, <sup>1</sup> Philippe S, <sup>3</sup> Cloutier Y, and <sup>1</sup> Zayed J.

<sup>1</sup> University of Montreal, Department of occupational and environmental health


<sup>2</sup> McGill, University, Meakins Christie Laboratories

<sup>3</sup> Institut de recherche en santé et sécurité au travail (IRSST)

<sup>4</sup> University of Quebec in Montreal

# Threshold limit value (TLV) for Be

 Quebec TWA-TLV : 2007 → **0,15  $\mu\text{g}/\text{m}^3$**

 Before 2007 → **2,0  $\mu\text{g}/\text{m}^3$**

 NIC → **0,05  $\mu\text{g}/\text{m}^3$  (ACGIH, 2008)**

# **Immunological reactions observed in affected individuals (BeS;CBD)**

- Be-specific hypersensitivity responses involving CD4+ T-lymphocytes.
- Production of T helper 1 (Th1) type cytokines.
- Inflammation in the lung.

# Risk factors

- Air Be concentration
- Particle size
- Chemical form
- Duration of exposure
- Genetic susceptibility of individuals



# Objective

**Assessment of the toxicity of Be  
following inhalation – nose only -  
exposure according to particle size  
and chemical species**

# Be species and particle sizes


## Three chemical forms

- Be
- BeO
- AlBe

## Two particle sizes

- Fine (F)
- Total (T)

# Acclimatization



# Intox Chamber



# Methods

- **Exposure duration : 6h/d, 5 d/w, 3 w**
- **245 mice, 7 Groups (n=35)**
  - 1: control group
  - 2: Be-T
  - 3: Be-F
  - 4: BeO-T
  - 5: BeO-F
  - 6: BeAl-T
  - 7: BeAl-F



# Methods

**Level of exposure → 250  $\mu\text{g}/\text{m}^3$**

- **One week after exposure, mice were sacrificed (28 d)**
- **5 mice/group were sacrificed 3 weeks after the end of exposure (42 d)**

# Monitoring

## **Evaluation of a methodology for Controlling Beryllium Exposure in laboratory setting**

**Results show that the protective measures  
applied during this research have been  
effective.**

# Tissue sampling

- Urine (1/week)
- Lung
- Spleen
- Liver
- Kidney
- Blood



# Analysis

- Tissue concentration (ICP-MS)
- Lung histology
- Cytokine measurement (ELISA)
- Flow Cytometry
- BeLPT



# RESULTS

# Be particle size in the inhalation chamber

Chemical form	MMAD ( $\mu\text{m} \pm \text{GSD}$ )
Be-T	4.1 $\pm$ 0.71
Be-F	1.5 $\pm$ 0.12
BeO-T	0.41 $\pm$ 0.14
BeO-F	0.41 $\pm$ 0.03
BeAl-T	6.5 $\pm$ 1.96
BeAl-F	4.4 $\pm$ 1.64


# Tissue concentrations

## Be-T vs BeAl-T





# Tissue concentrations

## Be-F vs BeO-F vs BeAl-F




# Tissue concentrations

## Be-F vs Be-T




# Tissue concentrations

## BeAl-F vs BeAl-T



# Flow Cytometry


## F vs T






# Flow Cytometry

## Be-F vs BeO-F vs BeAl-F




# Cytokine concentrations

## F vs T



# Cytokine concentrations


## Be-F vs BeO-F vs BeAl-F




# Histology of lung

## Mice exposed to Be


Control group




Be-F (1 week after exposure)



Be-T (1 week after exposure)



Be-F (3 weeks after exposure)







# Histology of lung

## Mice exposed to BeO


Control group



BeO-F (1 week after exposure)




BeO-F (3 weeks after exposure)




# Histology of lung in mice exposed to BeAl


Control group





BeAl-T (1 week after exposure)



BeAl-F (1 week after exposure)



BeAl-T (3 weeks after exposure) BeAl-F (3 weeks after exposure)





# Histological score of lung inflammation 1 week after the end of exposure

1:no inflammation  
2:mild inflammation  
3:moderate inflammation  
4:severe inflammation

	1	2	3
<b>CTL</b>	95,50%	4,50%	0
<b>Be-F</b>	0	54,50%	<b>45,50%</b>
<b>Be-T</b>	22,70%	68,20%	9,10%
<b>BeO-F</b>	22,70%	63,60%	13,60%
<b>BeAl-F</b>	44,40%	55,60%	0
<b>BeAl-T</b>	61,10%	38,90%	0

# Histological score of lung inflammation 3 weeks after the end of exposure

1:no inflammation

2:mild inflammation

3:moderate inflammation

4:severe inflammation

	1	2	3
<b>CTL</b>	91,70%	8,30%	0
<b>Be-F</b>	0	29,40%	<b>70,6%</b>
<b>BeO-F</b>	0	75%	25%
<b>BeAl-F</b>	0	77,80%	22,20%
<b>BeAl-T</b>	0	100%	0



# Conclusion

- ❁ What is the impact of **particle size** on Be toxicity ?
- Be tissue concentrations were significantly higher in mice exposed to Be-F and BeAl-F.
- Significant difference of lung inflammation between fine and total particles for Be and BeAl.
- Cytokine production was significantly higher in mice exposed to Be-F and BeAl-F.

# Conclusion

- What is the impact of **chemical form** on Be toxicity?

**For total particles:**

- ▢ Be in lung, spleen and liver were higher in mice exposed to Be compared to BeAl.
- ▢ Be concentrations were higher in blood in mice exposed to BeAl compared to Be.

# Conclusion

- What is the impact of **chemical form** on Be toxicity?

**For fine particles:**

- ▢ Be concentrations in lung were higher in mice exposed to BeO compared to Be and BeAl.
- ▢ Be concentrations in blood were higher in mice exposed to BeAl compared to Be and BeO.

# Conclusion

- What is the impact of **chemical form** on Be toxicity?
- Lung inflammation was significantly higher in mice exposed to Be than BeO.

# Conclusion

- **This study is a unique murine model to investigate the importance of particle size in producing chronic lung disease.**
- **Our results are a first attempt at duplicating the immunologic findings that characterize workers exposed to Be compounds at the workplace.**
- **This model will provide information allowing identification of a scientifically based threshold to protect workers against CBD.**

# Acknowledgements

## **University of Montreal**

**Dr. Joseph Zayed, director**  
**Lise Gareau, Elmirah Alyeva , Julianne Lama, Suzanne Philippe**

## **McGill University**

**Dr. Bruce Mazer**  
**Fariba Salehi**  
**Severine Audessou**

## **University of Quebec in Montreal**

**Dr. Gaston Chevalier**

## **IRSST**

**Ginette Truchon**  
**Yves Cloutier**

**This research was supported by the Institut de recherche Robert-Sauvé en santé et en sécurité du travail (IRSST), QUEBEC, CANADA.**

